Nasdaq Alternative Data
Nasdaq Medical Claims Insights
Unlock an in-depth view into the pharmaceutical and U.S. healthcare industries to drive more informed investment decisions and strategies.
What is Nasdaq Medical Claims Insights?
With Nasdaq Medical Claims Insights (NMCI), an exclusive Nasdaq dataset, access one of the most complete views of the US healthcare system, tracking longitudinal and real-time patient journeys of 250+ million unique individuals across HCPs, HCOs, and sites of care. NMCI provides extensive information on patient journeys including details on Rx, specialty pharmaceuticals, clinical records, EHR/EMR, payers, labs, and more. This data is anonymous and does not include any personally identifiable information.
Tracking the Entire Patient Journey
Nasdaq Medical Claims Insights Use Cases
Whether you are a quantitative hedge fund, a private equity firm exploring the healthcare industry, or a portfolio manager, gain access to new opportunities, insights, and strategies with Nasdaq Medical Claims Insights.
-
Track trends in the pharmaceutical and healthcare industries
-
Help forecast drug and company-level revenues
-
Analyze shifts in market share
-
Identify emerging drugs and companies
-
Stay ahead in this dynamic industry
Dive into the Data: GLP-1 Analysis with NMCI
In recent years, there has been significant growth in the GLP-1 treatment sector, with no indications of it slowing down. Utilize NMCI to track this continued growth and observe changes in medication use to help forecast shifts in market share among major manufacturers and players in the healthcare industry.
With NMCI, track transitions across different prescriptions and manufacturers to forecast emerging drugs and shifts in market share.
- In 2024, 51% of GLP-1 users were new GLP-1 users compared to 2023
- 12% of 2023 GLP-1 users switched from one GLP-1 medication to another in 2024
- 37% of 2023 users continued using the same medication in 2024
Understand the growth in this treatment space to forecast new trends and new investment opportunities
- The first GLP-1 drug was approved by the FDA in 2005
- Ozempic was approved at the end of 2017
- In last few years, we have seen massive growth in this treatment space
Contact Us
For detailed pricing information and to learn more about how our data sets can benefit your investment strategies, please contact us.
